December 1, 2013Journal of Cardiovascular Medicine
Identifying responsiveness to oral P2Y12 receptor blockers
Why the study?
Does platelet reactivity testing or genetic testing to tailor clopidogrel treatment reduce cardiovascular events in patients with ACS or undergoing PCI?
Population
Patients with acute coronary syndromes and/or who are undergoing percutaneous coronary interventions (PCI)
Comparison
Platelet reactivity testing and genetic testing… vs Standard of care
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Absence of conclusive data supports guideline-directed use of potent P2Y12 inhibitors without routine testing; leaves open targeted trials in high-risk ACS/PCI subgroups.
Structured PICO
Does platelet reactivity testing or genetic testing to tailor clopidogrel treatment reduce cardiovascular events in patients with ACS or undergoing PCI?
P
Population
Patients with acute coronary syndromes and/or who are undergoing percutaneous coronary interventions (PCI)
I
Intervention
Platelet reactivity testing (e.g., VerifyNow P2Y12 system) and genetic testing to tailor clopidogrel treatment
C
Comparator
Standard of care (current treatment guidelines and newer oral P2Y12 receptor blockers)
O
Outcome
Cardiovascular events
Definitive clinical evidence is lacking for the utility of using platelet reactivity data to tailor clopidogrel treatment, reinforcing adherence to current guidelines and use of newer P2Y12 inhibitors.
Cite This Study
Marco Valgimigli (2013) studied this question.